<DOC>
	<DOCNO>NCT00807196</DOCNO>
	<brief_summary>The purpose study investigate ability combine radioactive medication directly target lymphoma cell immune effect allogeneic blood stem cell transplant .</brief_summary>
	<brief_title>Zevalin With Non Myeloablative Allogeneic Stem Cell Transplantation Patients With Non Hodgkin Lymphoma</brief_title>
	<detailed_description>Despite initial high response rate low grade Non Hodgkin lymphoma , progressive refractory disease currently remain incurable . Being radiosensitive tumor , hypothesize combine different modality treatment include target radioimmunotherapy ( RIT ) , graft versus lymphoma effect relate allogeneic non myeloablative stem cell transplant may increase response survival rate safe manner patient persistent disease follow initial treatment . In study patient eligible standard stem cell transplant approach relapse refractory disease relate sibling donor treat RIT follow allogeneic non myeloablative blood stem cell transplant</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Patients must have/be 1 . Age 18 65 year . Patients age 66 69 may enrol judged excellent physical condition per treat physician study investigator base institutional practice . 2 . Diagnosis NonHodgkin lymphoma , follicular , marginal zone , small lymphocytic lymphoma , mantle cell lymphoma transform indolent NHL aggressive histology disease lymphoma define World Health Organization . 3 . Disease relapse , refractory fail achieve PR two cycle intensive salvage chemotherapy ( RESHAP ) disease relapse autologous stem cell transplantation . Poor partial response define less 50 % reduction tumor size . Salvage chemotherapy administer either 1st , 2nd 3rd relapse 4 . Disease express CD 20 antigen 5 . ECOG performance status 02 6 . Judged able tolerate NST Zevalin treatment base institutional criterion . 7 . Signed write informed consent 8 . At least one fully HLA match sibling without evident contraindication donation procedure willing sign consent donation Patients must have/be 1 . Abnormal renal function ( creatinine &gt; 1.5 x upper limit normal ( ULN ) 2 . Abnormal hepatic function ( bilirubin &gt; 2 x ULN , ALT/AST &gt; 2x ULN ) 3 . Cardiac ejection fraction &lt; 40 % and/or significant cardiac compromise 4 . Severe defect pulmonary function test receive continuous oxygen 5 . Severe concurrent illness , symptomatic congestive heart failure , severe arrhythmia , uncontrolled hypertension , diabetes , severe neurologic psychiatric disorder know HIV positive 6 . Previous concurrent cancer distinct primary site histology cancer evaluate except cervical carcinoma situ , treat basal cell carcinoma , superficial bladder tumor ( Ta , Tis &amp; T1 ) may impact patient life expectancy cancer curatively treat &lt; 3 year prior study entry . 7 . History prior allogeneic bone marrow transplant 8 . Evidence active hepatitis B C infection positivity hepatitisB surface antigen 9 . Known type 1 hypersensitivity anaphylactic protein component Zevalin therapy history presence human antimouse antibody ( HAMA ) 10 . A female patient pregnant breast feeding adult reproductive potential employ effective method birth control study . 11 . CNS lymphoma 12 . Ongoing confirm suspected significant infection 13 . Prior treatment radioimmunotherapy 14 . Other condition prevent participation standard NST 15 . No fully match sibling donor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2008</verification_date>
	<keyword>Allogeneic Stem Cell Transplantation</keyword>
	<keyword>Zevalin</keyword>
	<keyword>Non-Hodgkins Lymphoma</keyword>
</DOC>